Viatris (VTRS) Other Accumulated Expenses (2019 - 2026)
Viatris (VTRS) posted quarterly Other Accumulated Expenses of $3.1 billion for Q1 2026, down 13.77% year-over-year from $3.6 billion in Q1 2025, and down 4.66% quarter-over-quarter from $3.3 billion in Q4 2025.
Viatris (VTRS) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Viatris' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.1 billion for Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 13.77% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $3.1 billion (down 13.77% YoY), while the FY2025 annual figure was $3.3 billion, down 11.86% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $3.1 billion, down from $3.3 billion in the prior quarter.
- The five-year high for Other Accumulated Expenses was $4.4 billion in Q1 2022, with the low at $3.0 billion in Q2 2023.
- The 5-year median for Other Accumulated Expenses is $3.4 billion (2022), against an average of $3.5 billion.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses decreased 27.87% in 2023, then increased 16.27% in 2024.
- Viatris' Other Accumulated Expenses stood at $3.4 billion in 2022, then retreated by 1.37% to $3.4 billion in 2023, then gained by 9.75% to $3.7 billion in 2024, then decreased by 11.86% to $3.3 billion in 2025, then retreated by 4.66% to $3.1 billion in 2026.
- Business Quant data shows VTRS's Other Accumulated Expenses at $3.1 billion in Q1 2026, $3.3 billion in Q4 2025, and $3.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.88 Bn |
| Mar 31, 2026 | 3.13 Bn |
| Dec 31, 2025 | 3.28 Bn |
| Sep 30, 2025 | 3.62 Bn |
| Jun 30, 2025 | 3.67 Bn |
| Mar 31, 2025 | 3.63 Bn |
| Dec 31, 2024 | 3.72 Bn |
| Sep 30, 2024 | 3.86 Bn |
| Jun 30, 2024 | 3.23 Bn |
| Mar 31, 2024 | 3.28 Bn |
| Dec 31, 2023 | 3.39 Bn |
| Sep 30, 2023 | 3.32 Bn |
| Jun 30, 2023 | 3.05 Bn |
| Mar 31, 2023 | 3.19 Bn |
| Dec 31, 2022 | 3.44 Bn |
| Sep 30, 2022 | 3.50 Bn |
| Jun 30, 2022 | 3.81 Bn |
| Mar 31, 2022 | 4.43 Bn |
| Dec 31, 2021 | 4.62 Bn |
| Sep 30, 2021 | 4.63 Bn |